TG Therapeutics (TGTX) Tops Q4 EPS by 7c, provides outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cantor Fitzgerald Reiterates Overweight Rating on TG Therapeutics (TGTX)
March 3, 2025 1:07 PM ESTCantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on TG Therapeutics (NASDAQ: TGTX).
The analyst comments "TGTX stock is up >18% (XBI: -1%) on the back of positive comments on the 4Q call around 1Q trends for Briumvi (anti-CD20 drug in... More
